BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37957871)

  • 1. Curcumin Suppresses M2 Macrophage-derived Paclitaxel Chemoresistance through Inhibition of PI3K-AKT/STAT3 Signaling.
    Deswal B; Bagchi U; Kapoor S
    Anticancer Agents Med Chem; 2024; 24(2):146-156. PubMed ID: 37957871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway.
    Yang C; He L; He P; Liu Y; Wang W; He Y; Du Y; Gao F
    Med Oncol; 2015 Feb; 32(2):352. PubMed ID: 25572805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway.
    Lian G; Chen S; Ouyang M; Li F; Chen L; Yang J
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819849068. PubMed ID: 31088266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway.
    Zhang K; Li JY; Li K
    Chem Biol Drug Des; 2024 Jun; 103(6):e14559. PubMed ID: 38853025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages.
    Xing Z; Zhang M; Liu J; Liu G; Feng K; Wang X
    Mol Immunol; 2021 Oct; 138():1-9. PubMed ID: 34314939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
    Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
    Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel STAT3/ NFκB p50 axis regulates stromal-KDM2A to promote M2 macrophage-mediated chemoresistance in breast cancer.
    Chen JS; Teng YN; Chen CY; Chen JY
    Cancer Cell Int; 2023 Oct; 23(1):237. PubMed ID: 37821959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrazinocurcumin Encapsuled nanoparticles "re-educate" tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression.
    Zhang X; Tian W; Cai X; Wang X; Dang W; Tang H; Cao H; Wang L; Chen T
    PLoS One; 2013; 8(6):e65896. PubMed ID: 23825527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment.
    Yang YI; Wang YY; Ahn JH; Kim BH; Choi JH
    Biomed Pharmacother; 2022 Sep; 153():113474. PubMed ID: 36076499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization.
    Jang JY; Lee JK; Jeon YK; Kim CW
    BMC Cancer; 2013 Sep; 13():421. PubMed ID: 24044575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of curcumin and paclitaxel on breast carcinogenesis.
    Quispe-Soto ET; Calaf GM
    Int J Oncol; 2016 Dec; 49(6):2569-2577. PubMed ID: 27779649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
    Xiang F; Ni Z; Zhan Y; Kong Q; Xu J; Jiang J; Wu R; Kang X
    Tumour Biol; 2016 May; 37(5):6017-25. PubMed ID: 26596839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin inhibits the cancer‑associated fibroblast‑derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway.
    Ham IH; Wang L; Lee D; Woo J; Kim TH; Jeong HY; Oh HJ; Choi KS; Kim TM; Hur H
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35621145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of M2 macrophages modulating astrocyte polarization through the TGF-β/PI3K/Akt pathway.
    Pang QM; Zhang Q; Wu XC; Yang RL; Fu SP; Fan ZH; Liu J; Yu LM; Peng JC; Zhang T
    Immunol Lett; 2023 Jul; 259():1-8. PubMed ID: 37244460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
    Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
    Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform.
    Ying L; Zhu Z; Xu Z; He T; Li E; Guo Z; Liu F; Jiang C; Wang Q
    PLoS One; 2015; 10(6):e0129593. PubMed ID: 26115510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6.
    Yin Y; Yao S; Hu Y; Feng Y; Li M; Bian Z; Zhang J; Qin Y; Qi X; Zhou L; Fei B; Zou J; Hua D; Huang Z
    Clin Cancer Res; 2017 Dec; 23(23):7375-7387. PubMed ID: 28928161
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor-derived exosomal circFARSA mediates M2 macrophage polarization via the PTEN/PI3K/AKT pathway to promote non-small cell lung cancer metastasis.
    Chen T; Liu Y; Li C; Xu C; Ding C; Chen J; Zhao J
    Cancer Treat Res Commun; 2021; 28():100412. PubMed ID: 34119765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.